资讯
galecto完成战略审查，以聚焦肿瘤学和肝病，并从Bridge Medicines收购急性髓细胞白血病临床前资产
• galecto将专注于癌症和肝病，利用现有的临床阶段资产GB1211
• galecto通过获取BRm-1420的全球权利来强化其管线，这是一种新型双重ENL-YEATS和FLT3抑制剂，适用于急性髓系白血病（AML）的多个遗传亚型
• BRm-1420相较于单独使用FLT3抑制剂具有增强的临床有效性潜力，并且在临床前模型中已显示出与SOC的协同作用
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211, which has shown positive results in non-small cell lung cancer (NSCLC) and decompensated cirrhosis clinical studies. Galecto further announced that it has bolstered its pipeline with the acquisition of the global rights to BRm-1420, a novel, first-in-class asset developed by Bridge Medicines, a company co-founded by Takeda.
• galecto通过获取BRm-1420的全球权利来强化其管线，这是一种新型双重ENL-YEATS和FLT3抑制剂，适用于急性髓系白血病（AML）的多个遗传亚型
• BRm-1420相较于单独使用FLT3抑制剂具有增强的临床有效性潜力，并且在临床前模型中已显示出与SOC的协同作用
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211, which has shown positive results in non-small cell lung cancer (NSCLC) and decompensated cirrhosis clinical studies. Galecto further announced that it has bolstered its pipeline with the acquisition of the global rights to BRm-1420, a novel, first-in-class asset developed by Bridge Medicines, a company co-founded by Takeda.
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
